A Phase I Clinical Study to Evaluate Safety and Efficacy of C-TIL052A Cell Therapy (Autologous Tumor Infiltrating Lymphocytes Injection Combined With IL-2) in Subjects With Persistent, Recurrent and/or Metastatic Cervical Cancer
Latest Information Update: 18 Feb 2024
At a glance
- Drugs CTIL-052A (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
Most Recent Events
- 03 Aug 2022 New trial record